RABUWEL-20 INJECTION contains Rabeprazole Sodium 20 mg, an injectable proton pump inhibitor (PPI) designed for targeted acid-suppression therapy in acid-related gastrointestinal conditions. It selectively inhibits the gastric proton pump to reduce stomach acid secretion when oral administration is unsuitable or intravenous therapy is clinically indicated. An essential addition to a professional PCD Pharma Gastro and Critical Care portfolio.
It is used for acid-suppression therapy when intravenous rabeprazole is clinically indicated.
It reduces gastric acid secretion, but symptom relief depends on the condition.
No. It should be administered by qualified healthcare personnel.
Administer only under medical supervision and according to the prescribed dose and route. It is intended for situations where intravenous acid suppression is appropriate. Follow the manufacturer's reconstitution and administration instructions. Monitor patients for hypersensitivity reactions and clinical response.
Headache, nausea, abdominal discomfort, diarrhea, constipation and injection-site reactions may occur. Rarely, allergic reactions or significant gastrointestinal symptoms may develop. Report persistent or severe side effects to a healthcare professional.
RABUWEL-20 INJECTION contains Rabeprazole Sodium 20 mg, a proton pump inhibitor (PPI). It works by selectively inhibiting the gastric proton pump (H⁺/K⁺-ATPase) in stomach cells, reducing gastric acid secretion. This helps control excessive stomach acid and supports the management of acid-related gastrointestinal conditions when oral administration is unsuitable or intravenous therapy is clinically indicated.
